Putting the award page together from the records…
Putting the award page together from the records…
Mapp Biopharmaceutical, Inc. received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $76.73M obligated so far for health r&d services; health care services; experimental development. It runs to 2032-12-31, or to 2036-07-31 if every option is exercised.
Key facts · data as of Oct 22, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award 75A50122C00076, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_75A50122C00076_7505_-NONE-_-NONE-
Mapp Biopharmaceutical, Inc.: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
18 actions since 2023-02-10. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-14 | P00018 | Supplemental agreement (work within scope) | $44.34M | 75A50122C00076 EXERCISES OPTION 1 AND UPDATES SOW |
| 2026-07-13 | P00017 | Supplemental agreement (work within scope) | $0 | 75A50122C00076 TRANSFERS THE PROPERTY LISTED WITHIN THE MODIFICATION TO MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) BASE AGREEMENT NO. 2018-843, PROJECT AGREEMENT NO. 1 TO SUPPORT ANALYSIS OF GLYCOPROTEIN VARIANTS IN THE VSV-MARV-GP NEUTRALIZATION ASSAY F |
| 2026-05-14 | P00016 | Supplemental agreement (work within scope) | $0 | RECEIVE PROPERTY TRANSFERRED FROM HHSO100201900018C. |
| 2026-02-20 | P00015 | Supplemental agreement (work within scope) | $0 | TRANSFER PROPERTY TO HHSO100201600021C. |
| 2025-08-25 | P00014 | Administrative change | $0 | RECEIVE PROPERTY TRANSFER. |
| 2025-07-07 | P00013 | Administrative change | $0 | UPDATE COR TO SAIMA ZAMAN AND ALT-COR TO CAROL DIAZ-DIAZ. |
| 2025-05-07 | P00012 | Administrative change | $0 | UPDATE G.7 INDIRECT RATES OF CONTRACT NO. 75A50122C00076. |
| 2025-03-28 | P00011 | Supplemental agreement (work within scope) | $0 | CONTRACT NO. 75A50122C00076 SHALL TRANSFER GOVERNMENT FURNISHED PROPERTY (GFP) TO CONTRACT NO. 75A50124C00003. |
| 2025-02-28 | P00010 | Administrative change | $0 | THIS MOD UPDATES THE COR TO CAROL DIAZ-DIAZ AND REASSIGNS SAIMA ZAMAN AS THE ALT-COR. |
| 2025-01-30 | P00009 | Administrative change | $0 | THIS MOD UPDATES THE COR TO CAROL DIAZ-DIAZ AND REASSIGNS SAIMA ZAMAN AS THE ALT-COR. |
| 2024-12-13 | P00008 | Supplemental agreement (work within scope) | $0 | THIS MOD TRANSFERS GFP BETWEEN CONTRACTS. |
| 2024-11-15 | P00007 | Supplemental agreement (work within scope) | $0 | THIS MOD TRANSFERS GFP BETWEEN CONTRACTS. |
| 2024-09-24 | P00006 | Supplemental agreement (work within scope) | $0 | THIS MOD TRANSFERS GFP BETWEEN CONTRACTS. |
| 2024-05-21 | P00005 | Supplemental agreement (work within scope) | $0 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| 2024-03-08 | P00004 | Supplemental agreement (work within scope) | $0 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| 2023-08-07 | P00003 | Supplemental agreement (work within scope) | $12.56M | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| 2023-04-19 | P00002 | Supplemental agreement (work within scope) | $19.83M | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| 2023-02-10 | P00001 | Administrative change | $0 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗